Intranasal fentanyl versus intravenous morphine in the emergency department treatment of severe painful sickle cell crises in children: study protocol for a randomised controlled trial

Michael Joseph Barrett, John Cronin, Adrian Murphy, Siobhan McCoy, John Hayden, SinéadNic an Fhailí, Tim Grant, Abel Wakai, Corrina McMahon, Sean Walsh, Ronan O'Sullivan, Michael Joseph Barrett, John Cronin, Adrian Murphy, Siobhan McCoy, John Hayden, SinéadNic an Fhailí, Tim Grant, Abel Wakai, Corrina McMahon, Sean Walsh, Ronan O'Sullivan

Abstract

Background: Children with sickle cell disease (SCD) frequently and unpredictably present to the emergency department (ED) with pain. The painful event is the hallmark acute clinical manifestation of SCD, characterised by sudden onset and is usually bony in origin. This study aims to establish if 1.5mcg/kg of intranasal fentanyl (INF; administered via a Mucosal Atomiser Device, MAD™) is non-inferior to intravenous morphine 0.1 mg/kg in severe SCD-associated pain.

Methods/design: This study is a randomised,double-blind, double-dummy active control trial of children (weighing more than 10 kg) between 1 year and 21 years of age with severe painful sickle cell crisis. Severe pain is defined as rated seven or greater on a 0 to 10 age-appropriate numeric pain scale or equivalent. The trial will be conducted in a single tertiary urban paediatric ED in Dublin, Ireland. Each patient will receive a single active agent and a single placebo via the intravenous and intranasal routes. All clinical and research staff, patients and parents will be blinded to the treatment allocation. The primary endpoint is severity of pain scored at 10 min from administration of the study medications. Secondary endpoints include pain severity measured at 0, 5, 15, 20, 30, 60 and 120 min after the administration of analgesia, proportion of patients requiring rescue analgesia and incidence of adverse events. The trial ends at 120 min after the administration of the study drugs. A clinically meaningful difference in validated pain scores has been defined as 13 mm. Setting the permitted threshold to 50% of this limit (6 mm) and assuming both treatments are on average equal, a sample size of 30 patients (15 per group) will provide at least 80% power to demonstrate that INF is non-inferior to IV morphine with a level of significance of 0.05.

Discussion: This clinical trial will inform of the role of INF 1.5mcg/kg via MAD in the acute treatment of severe painful sickle cell crisis in children in the ED setting.

Trial registration: Current Controlled Trials ISRCTN67469672 and EudraCT no. 2011-005161-20.

Figures

Figure 1
Figure 1
Study flow chart. The schedule of study observations that will be recorded during the 120-min observation period.

References

    1. Yusuf HR, Atrash HK, Grosse SD, Parker CS, Grant AM. Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999–2007. Am J Prev Med. 2010;38:S536–541. doi: 10.1016/j.amepre.2010.01.001.
    1. McClain BC, Kain ZN. Pediatric palliative care: a novel approach to children with sickle cell disease. Pediatrics. 2007;119:612–614. doi: 10.1542/peds.2006-3580.
    1. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325:11–16. doi: 10.1056/NEJM199107043250103.
    1. Frei-Jones MJ, Baxter AL, Rogers ZR, Buchanan GR. Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment. J Pediatr. 2008;152:281–285. doi: 10.1016/j.jpeds.2007.06.040.
    1. Zempsky WT. Treatment of sickle cell pain: fostering trust and justice. JAMA. 2009;302:2479–2480. doi: 10.1001/jama.2009.1811.
    1. Zempsky WT. Evaluation and Treatment of Sickle Cell Pain in the Emergency Department: Paths to a Better Future. Clin Pediatr Emerg Med. 2010;11:265–273. doi: 10.1016/j.cpem.2010.09.002.
    1. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, Wethers DL, Smith J, Kinney TR. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342:83–89. doi: 10.1056/NEJM200001133420203.
    1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–1644. doi: 10.1056/NEJM199406093302303.
    1. Shapiro BS, Benjamin LJ, Payne R, Heidrich G. Sickle cell-related pain: perceptions of medical practitioners. J Pain Symptom Manage. 1997;14:168–174. doi: 10.1016/S0885-3924(97)00019-5.
    1. Todd KH, Green C, Bonham VL, Haywood C, Ivy E. Sickle cell disease related pain: crisis and conflict. J Pain. 2006;7:453–458.
    1. Smith LA, Oyeku SO, Homer C, Zuckerman B. Sickle cell disease: a question of equity and quality. Pediatrics. 2006;117:1763–1770. doi: 10.1542/peds.2005-1611.
    1. Kirsh KL, Whitcomb LA, Donaghy K, Passik SD. Abuse and addiction issues in medically ill patients with pain: attempts at clarification of terms and empirical study. Clin J Pain. 2002;18:S52–60. doi: 10.1097/00002508-200207001-00006.
    1. Solomon LR. Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void. Blood. 2008;111:997–1003.
    1. Klepstad P, Dale O, Skorpen F, Borchgrevink PC, Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005;49:902–908. doi: 10.1111/j.1399-6576.2005.00772.x.
    1. Darbari DS, Minniti CP, Rana S, van den Anker J. Pharmacogenetics of morphine: Potential implications in sickle cell disease. Am J Hematol. 2008;83:233–236. doi: 10.1002/ajh.21027.
    1. Darbari DS, Neely M, van den Anker J, Rana S. Increased clearance of morphine in sickle cell disease: implications for pain management. J Pain. 2011;12:531–538. doi: 10.1016/j.jpain.2010.10.012.
    1. Jacobson SJ, Kopecky EA, Joshi P, Babul N. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet. 1997;350:1358–1361. doi: 10.1016/S0140-6736(97)08462-6.
    1. Kavanagh PL, Sprinz PG, Vinci SR, Bauchner H, Wang CJ. Management of children with sickle cell disease: a comprehensive review of the literature. Pediatrics. 2011;128:e1552–1574. doi: 10.1542/peds.2010-3686.
    1. Holsti M, Dudley N, Schunk J, Adelgais K, Greenberg R, Olsen C, Healy A, Firth S, Filloux F. Intranasal Midazolam vs Rectal Diazepam for the Home Treatment of Acute Seizures in Pediatric Patients With Epilepsy. Arch Pediatr Adolesc Med. 2010;164:747–753.
    1. Karl HW, Keifer AT, Rosenberger JL, Larach MG, Ruffle JM. Comparison of the safety and efficacy of intranasal midazolam or sufentanil for preinduction of anesthesia in pediatric patients. Anesthesiology. 1992;76:209–215. doi: 10.1097/00000542-199202000-00009.
    1. Striebel HW, Olmann T, Spies C, Brummer G. Patient-controlled intranasal analgesia (PCINA) for the management of postoperative pain: a pilot study. J Clin Anesth. 1996;8:4–8. doi: 10.1016/0952-8180(95)00167-0.
    1. Galinkin JL, Fazi LM, Cuy RM, Chiavacci RM, Kurth CD, Shah UK, Jacobs IN, Watcha MF. Use of intranasal fentanyl in children undergoing myringotomy and tube placement during halothane and sevoflurane anesthesia. Anesthesiology. 2000;93:1378–1383. doi: 10.1097/00000542-200012000-00006.
    1. Holdgate A, Cao A, Lo KM. The implementation of intranasal fentanyl for children in a mixed adult and pediatric emergency department reduces time to analgesic administration. Acad Emerg Med. 2010;17:214–217. doi: 10.1111/j.1553-2712.2009.00636.x.
    1. Borland ML, Clark LJ, Esson A. Comparative review of the clinical use of intranasal fentanyl versus morphine in a paediatric emergency department. Emerg Med Australas. 2008;20:515–520. doi: 10.1111/j.1742-6723.2008.01138.x.
    1. Chung S, Lim R, Goldman RD. Intranasal fentanyl versus placebo for pain in children during catheterization for voiding cystourethrography. Pediatr Radiol. 2010;40:1236–1240. doi: 10.1007/s00247-009-1521-1.
    1. Borland ML, Bergesio R, Pascoe EM, Turner S, Woodger S. Intranasal fentanyl is an equivalent analgesic to oral morphine in paediatric burns patients for dressing changes: a randomised double blind crossover study. Burns. 2005;31:831–837. doi: 10.1016/j.burns.2005.05.001.
    1. Finn M, Harris D. Intranasal fentanyl for analgesia in the paediatric emergency department. Emerg Med J. 2010;27:300–301. doi: 10.1136/emj.2008.070474.
    1. Saunders M, Adelgais K, Nelson D. Use of intranasal fentanyl for the relief of pediatric orthopedic trauma pain. Acad Emerg Med. 2010;17:1155–1161. doi: 10.1111/j.1553-2712.2010.00905.x.
    1. Crellin D, Ling RX, Babl FE. Does the standard intravenous solution of fentanyl (50 microg/mL) administered intranasally have analgesic efficacy? Emerg Med Australas. 2010;22:62–67. doi: 10.1111/j.1742-6723.2010.01257.x.
    1. Cole J, Shepherd M, Young P. Intranasal fentanyl in 1-3-year-olds: a prospective study of the effectiveness of intranasal fentanyl as acute analgesia. Emerg Med Australas. 2009;21:395–400. doi: 10.1111/j.1742-6723.2009.01216.x.
    1. Borland M, Jacobs I, King B, O'Brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med. 2007;49:335–340. doi: 10.1016/j.annemergmed.2006.06.016.
    1. Telfer P, Criddle J, Sandell J, Davies F, Morrison I, Challands J. Intranasal diamorphine for acute sickle cell pain. Arch Dis Child. 2009;94:979–980. doi: 10.1136/adc.2008.138875.
    1. Borland ML, Jacobs I, Geelhoed G. Intranasal fentanyl reduces acute pain in children in the emergency department: a safety and efficacy study. Emerg Med (Fremantle) 2002;14:275–280. doi: 10.1046/j.1442-2026.2002.00344.x.
    1. Manjushree R, Lahiri A, Ghosh BR, Laha A, Handa K. Intranasal fentanyl provides adequate postoperative analgesia in pediatric patients. Can J Anaesth. 2002;49:190–193. doi: 10.1007/BF03020494.
    1. Younge PA, Nicol MF, Kendall JM, Harrington AP. A prospective randomized pilot comparison of intranasal fentanyl and intramuscular morphine for analgesia in children presenting to the emergency department with clinical fractures. Emergency Medicine. 1999;11:90–94. doi: 10.1046/j.1442-2026.1999.00020.x.
    1. Johnston S, Wilkes GJ, Thompson JA, Ziman M, Brightwell R. Inhaled methoxyflurane and intranasal fentanyl for prehospital management of visceral pain in an Australian ambulance service. Emerg Med J. 2011;28:57–63. doi: 10.1136/emj.2009.078717.
    1. Bendall JC, Simpson PM, Middleton PM. Effectiveness of prehospital morphine, fentanyl, and methoxyflurane in pediatric patients. Prehosp Emerg Care. 2011;15:158–165. doi: 10.3109/10903127.2010.541980.
    1. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002;46:759–770. doi: 10.1034/j.1399-6576.2002.460702.x.
    1. Wolfe TR, Braude DA. Intranasal medication delivery for children: a brief review and update. Pediatrics. 2010;126:532–537. doi: 10.1542/peds.2010-0616.
    1. Andrews C. P-R: Fentanyl: a review. Clin Anaesthesiol. 1983. pp. 97–122.
    1. Kelly AM. Does the clinically significant difference in visual analog scale pain scores vary with gender, age, or cause of pain? Acad Emerg Med. 1998;5:1086–1090. doi: 10.1111/j.1553-2712.1998.tb02667.x.
    1. Todd KH, Funk KG, Funk JP, Bonacci R. Clinical Significance of Reported Changes in Pain Severity. Ann Emerg Med. 1996;27:485–489. doi: 10.1016/S0196-0644(96)70238-X.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner